Gunnar Gårdemyr, a pharmaceutical industry veteran, has been appointed chief executive officer of Targovax A/S, a Norway-based developer of cancer vaccines. The appointment will take effect on 12 January 2015. Mr Gårdemyr is currently a corporate advisor to Acino Pharma, a developer of drug delivery technologies which is based in Basel, Switzerland. Prior to this, he was senior vice president for corporate development at Nycomed, which was acquired by Takeda Pharmaceutical Company Ltd in 2011.
Mr Gårdemyr has a Bachelor of Science degree in business administration and economics from the University of Lund in Sweden.
Targovax announced the appointment on 5 November 2014.
Copyright 2014 Evernow Publishing Ltd